MX359638B - Vacunas basadas en el virus de la parainfluenza 5. - Google Patents
Vacunas basadas en el virus de la parainfluenza 5.Info
- Publication number
- MX359638B MX359638B MX2014008557A MX2014008557A MX359638B MX 359638 B MX359638 B MX 359638B MX 2014008557 A MX2014008557 A MX 2014008557A MX 2014008557 A MX2014008557 A MX 2014008557A MX 359638 B MX359638 B MX 359638B
- Authority
- MX
- Mexico
- Prior art keywords
- gene
- nucleotide sequence
- genome
- parainfluenza virus
- heterologous nucleotide
- Prior art date
Links
- 241001559185 Mammalian rubulavirus 5 Species 0.000 title abstract 4
- 229960005486 vaccine Drugs 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 4
- 239000002773 nucleotide Substances 0.000 abstract 3
- 125000003729 nucleotide group Chemical group 0.000 abstract 3
- 101710200413 Small hydrophobic protein Proteins 0.000 abstract 2
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 abstract 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 abstract 1
- 239000013604 expression vector Substances 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/205—Rhabdoviridae, e.g. rabies virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16171—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18711—Rubulavirus, e.g. mumps virus, parainfluenza 2,4
- C12N2760/18721—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18711—Rubulavirus, e.g. mumps virus, parainfluenza 2,4
- C12N2760/18732—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18711—Rubulavirus, e.g. mumps virus, parainfluenza 2,4
- C12N2760/18741—Use of virus, viral particle or viral elements as a vector
- C12N2760/18743—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18711—Rubulavirus, e.g. mumps virus, parainfluenza 2,4
- C12N2760/18771—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20111—Lyssavirus, e.g. rabies virus
- C12N2760/20134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20111—Lyssavirus, e.g. rabies virus
- C12N2760/20171—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La presente invención se refiere a vacunas seguras, estables, eficaces y económicas basadas en los vectores de expresión viral que incluyen un genoma del virus de la parainfluenza 5 (PIV5) que incluyen una secuencia nucleotídica heteróloga que expresa un polipéptido heterólogo. En algunas modalidades, la secuencia nucleotídica heteróloga se inserta más cerca del líder que entre el gen hemaglutinina-neuraminidasa (HN) y el gen de la proteína (L) ARN polimerasa grande del genoma PIVS. En algunas modalidades, la secuencia nucleotídica heteróloga se inserta entre el gen de la proteína hidrófoba pequeña (SH) y el gen hemaglutinina-neuraminidasa (HN) del genoma PIV5.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261590070P | 2012-01-24 | 2012-01-24 | |
US201261590056P | 2012-01-24 | 2012-01-24 | |
US201261683810P | 2012-08-16 | 2012-08-16 | |
PCT/US2013/022962 WO2013112720A1 (en) | 2012-01-24 | 2013-01-24 | Parainfluenza virus 5 based vaccines |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2014008557A MX2014008557A (es) | 2014-10-24 |
MX359638B true MX359638B (es) | 2018-10-04 |
Family
ID=48873896
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2014008557A MX359638B (es) | 2012-01-24 | 2013-01-24 | Vacunas basadas en el virus de la parainfluenza 5. |
Country Status (13)
Country | Link |
---|---|
US (6) | US9505807B2 (es) |
EP (2) | EP3536341A1 (es) |
JP (3) | JP6228136B2 (es) |
CN (2) | CN108130345A (es) |
AU (1) | AU2013212097B2 (es) |
BR (1) | BR112014018179B1 (es) |
CA (2) | CA2860388C (es) |
ES (1) | ES2728248T3 (es) |
MX (1) | MX359638B (es) |
MY (1) | MY173638A (es) |
PH (1) | PH12014501255A1 (es) |
PT (1) | PT2806891T (es) |
WO (2) | WO2013112720A1 (es) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2678043B1 (en) | 2011-02-25 | 2018-04-25 | University Of Georgia Research Foundation, Inc. | Recombinant mumps virus vaccine |
CN108130345A (zh) | 2012-01-24 | 2018-06-08 | 乔治亚大学研究基金公司 | 基于副流感病毒5的疫苗 |
KR101577397B1 (ko) * | 2014-01-15 | 2015-12-28 | 경북대학교 산학협력단 | 신규한 돼지 파라인플루엔자 바이러스 5(pPIV5), 이를 포함하는 백신 조성물 및 이를 이용한 돼지 파라인플루엔자 바이러스 검정 키트 |
EP3288595B1 (en) | 2015-04-28 | 2020-12-30 | The University Of Georgia Research Foundation, Inc. | Piv5-based amplifying virus-like particles |
US20180339038A1 (en) * | 2015-06-12 | 2018-11-29 | Mie University | Human parainfluenza virus type 2 vector and vaccine |
US11684637B2 (en) * | 2017-05-25 | 2023-06-27 | University Of Central Florida Research Foundation, Inc. | Oncolytic viruses for sensitizing tumor cells to killing by natural killer cells |
RU2681473C1 (ru) * | 2018-01-16 | 2019-03-06 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Кубанский государственный аграрный университет имени И.Т. Трубилина" | Тест-система для обнаружения генома вируса парагриппа 3 типа у крупного рогатого скота с помощью мультиплексной полимеразной цепной реакции с флуоресцентной детекцией в режиме реального времени |
GB201816873D0 (en) * | 2018-10-17 | 2018-11-28 | Imperial Innovations Ltd | Fusion protein |
WO2020092207A1 (en) * | 2018-10-28 | 2020-05-07 | University Of Georgia Research Foundation | Broadly reactive immunogens of influenza virus, compositions, and methods of use thereof |
CL2018003869A1 (es) * | 2018-12-28 | 2021-01-15 | Univ Pontificia Catolica Chile | Anticuerpos monoclonales específicos para la proteína quimérica l del virus de la parainfluenza humana (piv), secuencias nucleotídicas; método y kit de diagnóstico de infección producida por piv |
EP4213872A4 (en) * | 2020-09-21 | 2024-03-27 | University of Georgia Research Foundation, Inc. | PIV5 VACCINE AGAINST COVID-19 |
WO2022099185A1 (en) * | 2020-11-09 | 2022-05-12 | Thrive Bioscience, Inc. | Plaque counting assay method |
CN113005149A (zh) * | 2021-03-26 | 2021-06-22 | 中国农业大学 | 一种表达冠状病毒受体结合域串联二聚体的重组副流感病毒5型载体 |
WO2023028012A1 (en) * | 2021-08-26 | 2023-03-02 | University Of Georgia Research Foundation, Inc. | J paramyxovirus vaccines |
GB202209861D0 (en) * | 2022-07-05 | 2022-08-17 | Univ Court Univ St Andrews | Viral vectors |
WO2024097976A1 (en) * | 2022-11-04 | 2024-05-10 | Blue Lake Biotechnology, Inc. | Recombinant rsv vaccine: methods of making and using the same |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6638762B1 (en) | 1994-11-28 | 2003-10-28 | Genetic Therapy, Inc. | Tissue-vectors specific replication and gene expression |
CA2160038A1 (en) * | 1995-07-14 | 1997-01-15 | Biosignal Inc. | Methods of screening compounds for their pharmacological relevance based on downregulation of recombinant receptors |
CA2253595A1 (en) | 1996-05-01 | 1997-11-06 | The Government Of The United States Of America, Represented By The Secre Tary, Department Of Health And Human Services | Generation of viral transfectants using recombinant dna-derived nucleocapsid proteins |
US6410023B1 (en) * | 1997-05-23 | 2002-06-25 | United States Of America | Recombinant parainfluenza virus vaccines attenuated by deletion or ablation of a non-essential gene |
US5962274A (en) * | 1998-03-13 | 1999-10-05 | Wake Forest University | Viral vector directed to predetermined target cells |
EP1179054A2 (en) * | 1999-12-10 | 2002-02-13 | The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services | Use of recombinant parainfluenza viruses (pivs) as vectors to protect against infection and disease caused by piv and other human pathogens |
US6764685B1 (en) * | 2000-03-21 | 2004-07-20 | Medimmune Vaccines, Inc. | Recombinant parainfluenza virus expression systems and vaccines |
JP2002153278A (ja) | 2000-11-22 | 2002-05-28 | Hisamitsu Pharmaceut Co Inc | ウイルスベクターの製造に用いられる細胞、その製法およびその細胞を用いたウイルスベクターの製造方法 |
AU2002327755A1 (en) * | 2001-09-28 | 2003-04-14 | Rush-Presbyterian-St. Luke's Medical Center | Paramyxoviruses as gene transfer vectors to lung cells |
ATE555208T1 (de) | 2003-06-13 | 2012-05-15 | Apath Llc | Replikon eines negativsträngigen rna-virus |
ES2542644T3 (es) | 2007-07-19 | 2015-08-07 | Novavax, Inc. | VLPS quiméricas de la gripe aviar |
US20090208495A1 (en) * | 2008-02-14 | 2009-08-20 | Bayer Schering Pharma Ag | Anti-tumor effective paramyxovirus |
FR2938840B1 (fr) | 2008-11-21 | 2010-12-17 | Centre Nat Rech Scient | Proteines mutantes de la proteine f de piv-5 et de piv-2 |
US10227569B2 (en) | 2011-04-12 | 2019-03-12 | Emory University | Respiratory syncytial virus expression vectors |
CN108130345A (zh) | 2012-01-24 | 2018-06-08 | 乔治亚大学研究基金公司 | 基于副流感病毒5的疫苗 |
-
2013
- 2013-01-24 CN CN201810061733.4A patent/CN108130345A/zh active Pending
- 2013-01-24 EP EP19165071.2A patent/EP3536341A1/en active Pending
- 2013-01-24 WO PCT/US2013/022962 patent/WO2013112720A1/en active Application Filing
- 2013-01-24 BR BR112014018179-9A patent/BR112014018179B1/pt active IP Right Grant
- 2013-01-24 CA CA2860388A patent/CA2860388C/en active Active
- 2013-01-24 US US14/374,061 patent/US9505807B2/en active Active
- 2013-01-24 ES ES13741216T patent/ES2728248T3/es active Active
- 2013-01-24 US US14/374,070 patent/US9732358B2/en active Active
- 2013-01-24 CA CA3128591A patent/CA3128591A1/en active Pending
- 2013-01-24 CN CN201380006495.2A patent/CN104093422B/zh active Active
- 2013-01-24 PT PT13741216T patent/PT2806891T/pt unknown
- 2013-01-24 MX MX2014008557A patent/MX359638B/es active IP Right Grant
- 2013-01-24 MY MYPI2014702016A patent/MY173638A/en unknown
- 2013-01-24 WO PCT/US2013/022898 patent/WO2013112690A1/en active Application Filing
- 2013-01-24 AU AU2013212097A patent/AU2013212097B2/en active Active
- 2013-01-24 JP JP2014554824A patent/JP6228136B2/ja active Active
- 2013-01-24 EP EP13741216.9A patent/EP2806891B1/en active Active
-
2014
- 2014-06-04 PH PH12014501255A patent/PH12014501255A1/en unknown
-
2016
- 2016-10-18 US US15/296,346 patent/US10752916B2/en active Active
-
2017
- 2017-06-30 US US15/638,946 patent/US10329585B2/en active Active
- 2017-10-12 JP JP2017198111A patent/JP2018050624A/ja active Pending
-
2019
- 2019-05-24 US US16/421,837 patent/US20190284578A1/en not_active Abandoned
- 2019-09-18 JP JP2019168928A patent/JP6900437B2/ja active Active
-
2020
- 2020-08-10 US US16/989,038 patent/US11542527B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12014501255A1 (en) | Parainfluenza virus 5 based vaccines | |
PH12019501130A1 (en) | Viral delivery of neoantigens | |
TN2018000155A1 (en) | Herpes simplex virus vaccine | |
WO2014152432A3 (en) | Rna-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci | |
AU2016262093A8 (en) | Enhancing endonuclease based gene editing in primary cells | |
MX357803B (es) | Moléculas de ácido nucleico artificiales. | |
EA201692359A1 (ru) | Композиция на основе нового штамма prrsv или его белков, продукт, их применение, вирус prrsv, выделенная нк и рекомбинантный вектор экспрессии для получения этого вируса | |
MY187152A (en) | Stabilized human immunodeficiency virus (hiv) envelope (env) trimer vaccines and methods of using same | |
MX352974B (es) | Moleculas de acido nucleico que codifican novedosos antigenos de herpes, vacunas que las comprenden y metodos para su uso. | |
WO2007002008A3 (en) | Methods and compositions for expressing negative-sense viral rna in canine cells | |
WO2015052543A3 (en) | Malaria vaccination | |
MX2017008504A (es) | Vacuna para enfermedad de newcastle y de bursitis infecciosa (nd-ibd) en vector de hvt mejorada. | |
WO2007124327A3 (en) | Methods and compositions for expressing negative-sense viral rna in canine cells | |
WO2011072247A8 (en) | Pathogen restriction factors | |
MX2014007516A (es) | Procesos que utilizan vlps con capsides resistentes a hidrolasas. | |
PH12016500500A1 (en) | A viral vaccine and methods of manufacture thereof | |
MA37749B1 (fr) | Vaccins contre les virus réassortis de la fièvre catarrhale et de la peste équine | |
EA201691120A1 (ru) | Векторные композиции и способы индукции усиленного иммунного ответа с использованием векторов поксвируса | |
EA201890351A1 (ru) | Рекомбинантный orf-вирусный вектор | |
MX2015016765A (es) | Celulas aviares para la produccion mejorada de virus. | |
WO2012116253A3 (en) | Recombinant mumps virus vaccine | |
MX2017006671A (es) | Plásmidos y método para obtener partículas virales. | |
WO2013046216A3 (en) | Two plasmid mammalian expression system | |
EA202090628A1 (ru) | Система экспрессии paramyxoviridae | |
WO2013163085A3 (en) | Glycaspis brimblecombei control agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |